Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Targovax and Oslo University Hospital Announce Collaboration To Test TG Mutant RAS Vaccination in Multiple Myeloma
Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid […]
TheraVet Signs an Important Distribution Agreement With the Orthopaedics & Surgical Instrumentation Distributor, Veterinary Instrumentation
TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases […]
Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration […]
RayCare In Clinical Use With CyberKnife at Swiss Medical Network in Switzerland
RaySearch Laboratories AB (publ) announces that La Clinique Générale-Beaulieu, a part of Swiss Medical Network […]
Adaptiiv Collaborates With HP and Varian To Enhance Personalization in Radiation Oncology With 3D Printed Medical Devices
Adaptiiv Medical Technologies Inc. (Adaptiiv) is collaborating with HP Inc. (HP) and Varian, a Siemens […]
CHOP Researchers Develop New Computational Tool to Interpret Clinical Significance of Cancer Mutations
Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a new tool to help researchers interpret […]
InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers
InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug […]
Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris (ravulizumab-cwvz) achieved a statistically […]
Farxiga Met Primary Endpoint in DELIVER Phase III Trial, Reducing Risk of Cardiovascular Death or Worsening Heart Failure in Patients with Preserved Ejection Fraction
High-level results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) reached a statistically […]
Enhertu Approved in the US for Patients with HER2-positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-based Regimen
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more